Physician profile
Timothy J Allen
NPI 1164425898
$30,506.77
in general payments reported to CMS, 2019-2025
62 companies · $5,273 in 2025
The $5,273 reported for 2025 was more than what 85% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,405 · 2020: $2,597 · 2021: $4,443 · 2022: $4,236 · 2023: $3,826 · 2024: $4,727 · 2025: $5,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $10.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,815.99 |
| Education | $10.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $5,319.84 | 2019-2025 | |
| Biogen, INC. | $3,420.06 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Emd Serono, INC. | $3,400.46 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,733.18 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Alexion Pharmaceuticals, INC. | $1,390.87 | 2019-2025 | Ultomiris |
| Neurocrine Biosciences, INC. | $1,310.86 | 2020-2025 | Ingrezza, Ongentys |
| Amgen INC. | $1,268.51 | 2019-2024 | Aimovig |
| Celgene Corporation | $953.71 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $922.90 | 2020-2025 | Kisunla, Amyvid, Reyvow |
| Genzyme Corporation | $910.74 | 2019-2025 | |
| Tg Therapeutics, INC. | $860.03 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $841.51 | 2019-2022 | |
| Lundbeck LLC | $748.94 | 2020-2025 | Vyepti, Rexulti |
| Ucb, INC. | $654.61 | 2023-2025 | Fintepla, Zilbrysq, Rystiggo |
| Biohaven Pharmaceuticals, INC. | $521.05 | 2020-2021 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Allen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.